免疫療法の領域における青写真は、過去10年間に単一特異性抗体や二重特異性抗体などの抗体療法が出現したことで、未来的なものと認識されてきました。この調査は、非ホジキンリンパ腫に苦しむ患者の管理のために最初のモノクローナル抗体であるリツキシマブがFDAに承認された後、その歩みを取り戻しました。単一特異性抗体は大きな勝利を収めていますが、1種類の抗原しか標的にできないことや治療抵抗性が高まるなど、多くの落とし穴があり、体内の複数の抗原や外敵を標的とする治療法をさらに開発する必要性が高まっています。近年、三重特異性抗体は、3つの抗原を同時に標的とする妥当性から、有望な治療標的として浮上しており、様々な疾患への介入のゲームチェンジャー候補となっています。
現在まで、三重特異性抗体は市場に投入されていません。しかし、近い将来、一握りの三特異性抗体が承認される可能性が高まっています。医療従事者は、単一特異性抗体の成果に基づいて、3つの異なる抗原に同時に結合できる三重特異性抗体を開発し、腫瘍細胞を標的とする精度と有効性を高めています。これはがん免疫療法の分野における画期的なイノベーションです。
目次
Table of Content
1. Trispecific Antibody As Targeted Therapy
2. Trispecific Antibody Current Clinical Development and Future Commercialization Outlook
2.1. Current Market Development Scenario
2.2. Future Market Commercialization Outlook
3. Trispecific Antibody Clinical and Market Development Trend Analysis by Region
3.1. US
3.2. China
3.3. EU
3.4. UK
3.5. Japan
3.6. Australia
4. Trispecific Antibodies Therapeutic Clinical Tends By Indications
4.1. Cancer
4.1.1. Breast Cancer
4.1.2. Colorectal Cancer
4.1.3. Lung Cancer
4.1.4. Multiple Myeloma
4.1.5. Lymphoma
4.1.6. Leukemia
4.2. Viral Infections
4.3. Eye Diseases
5. Global Trispecific Antibodies Clinical Trials Overview
5.1. By Country
5.2. By Phase
5.3. By Company
5.4. By Indication
5.5. By Patient Segment
6. Global Trispecific Antibodies Clinical Trials Insight By Company, Country, Indication and Phase
6.1. Research
6.2. Preclinical
6.3. Phase I
6.4. Phase I/II
7. Trispecific Antibody Market Dynamics
7.1. Market Drivers
7.2. Market Challenges
8. Recent Trends in Trispecific Antibody Market: Partnerships, Acquisitions, Collaboration, and Investments
9. Combinations Approaches for Bourgeoning Trispecific Antibody
9.1. Immunotherapy
9.2. Radiotherapy
10. Platforms Used For Pioneering Trispecific Antibody
10.1. Tavotek Biotherapeutics - TavoSelect Platform
10.2. Tavotek Biotherapeutics - TavoPrecise Platform
10.3. Purple Biotech - Tribody Antibody Platform
10.4. Simcere Zaiming's - T-Cell Engager Polyspecific Antibody Technology Platform
10.5. Ichnos Sciences - BEAT Platform
10.6. Molecular Partners - DARPin Platform
10.7. Merus - Triclonics Platform
11. Competitive Landscape
11.1. AbbVie
11.2. Antibody Studio
11.3. Beijing Mabworks Biotech
11.4. Biocytogen Pharmaceuticals
11.5. Chimagen Biosciences
11.6. Chiome Bioscience
11.7. Genor Biopharma
11.8. GT Biopharma
11.9. Harpoon Therapeutics
11.10. Ichnos Sciences
11.11. KisoJi Biotechnology
11.12. L and L Biopharma
11.13. Lyvgen Biopharma
11.14. Numab
11.15. OPKO Health
11.16. Sanofi
11.17. Sichuan Baili Pharmaceuticals
11.18. TG ImmunoPharma
List of Figures & Table
Figure 1-1: Trispecific Antibody as Targeted Therapy
Figure 2-1: Strategies to Develop Next Generation Trispecific Antibody
Figure 2-2: Aspects Influencing Future of Trispecific Antibody
Figure 3-1: CB307 Phase I Study (NCT04839991) - Initiation and Completion Year
Figure 3-2: SAIL66 Phase I Study (NCT05735366) - Initiation and Completion Year
Figure 4-1: BR115 Phase I Study (NCT06388902) - Initiation and Completion Year
Figure 4-2: NM32-2668 Phase I Study (NCT06299163) - Initiation and Completion Year
Figure 4-3: Trispecific Antibody Benefit to Treat Colorectal Cancer
Figure 4-4: Chimagen Biosciences Pipeline
Figure 4-5: HPN328 (MK-6070) with Atezolizumab Phase I/II Study (NCT04471727) - Initiation and Completion Year
Figure 4-6: Genor Biopharma Pipeline
Figure 4-7: GB263T Phase I/II Study (NCT05332574) - Initiation and Completion Year
Figure 4-8: SIM0500 Phase I Study (NCT06375044) - Initiation and Completion Year
Figure 4-9: JNJ-79635322 Phase I Study (NCT05652335) - Initiation and Completion Year
Figure 4-10: MBS314 Phase I/II Study (NCT06232096) - Initiation and Completion Year
Figure 4-11: Trispecific Antibodies FDA Designations
Figure 4-12: HPN217 Phase I Study (NCT04184050) - Initiation and Completion Year
Figure 4-13: PIT565 Phase I Study (NCT05397496) - Initiation and Completion Year
Figure 4-14: JNJ-80948543 Phase I Study (NCT05424822) - Initiation and Completion Year
Figure 4-15: 1A46/ BR110 Phase I/II Study (NCT05987605) - Initiation and Completion Year
Figure 4-16: KL-HIV-Tri01 Phase I Study (NCT06117657) - Initiation and Completion Year
Figure 4-17: Restoret (EYE103) - Tetravalent, Tri-Specific Antibody Binding Sites
Figure 4-18: Restoret/ EYE103 Phase I/II Study (NCT05919693) - Initiation and Completion Year
Figure 4-19: Eluminex Ophthalmics Clinical Trispecific Pipeline for Eye Ailments
Figure 5-1: Global - Trispecific Antibodies Clinical Trials by Country, 2024
Figure 5-2: Global - Trispecific Antibodies Clinical Trials by Phase, 2024
Figure 5-3: Global - Trispecific Antibodies Clinical Trials by Company, ?
Figure 5-4: Global - Trispecific Antibodies Clinical Trials by Indication, 2024
Figure 5-5: Global - Trispecific Antibodies Clinical Trials by Patient Segment, 2024
Figure 7-1 : Trispecific Antibody - Market Drivers
Figure 7-2: Key Players in Trispecific Antibody Market
Figure 7-3: Trispecific Antibody - Market Challenges
Figure 9-1: JNJ-87801493 with JNJ-80948543 and JNJ-75348780 Phase I Study (NCT06139406) - Initiation and Completion Year
Figure 9-2: Radiolabelled CB307/ 89Zr-CB307 Phase I Study (NCT05836623) - Initiation and Completion Year
Figure 10-1: Purple Biotech - Tribody Antibody Platform
Figure 10-2: DARPin Platform - Molecular Partners
Figure 10-3: Merus - Triclonics Platform
Figure 11-1: GT Biopharma - Clinical Pipeline
Table 3-1: US -Ongoing Clinical Trials for Trispecific Antibodies (May’2024)
Table 3-2: EU -Ongoing Clinical Trials for Trispecific Antibodies (May’2024)
Table 3-3: Australia -Ongoing Clinical Trials for Trispecific Antibodies (May’2024)
